Dave Solis Email & Phone Number

San Diego, Ca, Us

• Established and currently leads the screening and SAR laboratory for small molecule drug discovery.• Oversees the design, development, validation and implementation of biochemical and cell-based in vitro pharmacology readouts for small molecule profiling, as well as laboratory automation and data informatics processes. • As core member of project teams, provides guidance on establishing screening cascades and compound profiling workflows for multiple programs.• Identifies, selects and manages CRO partners for HTS campaigns and orthogonal follow up efforts. Performs data analysis and QC applying established internal business rules, and subsequent transfer to in-house research informatics database. • Partners with research informatics software developers in establishing assay workflows for high throughput data analysis, capture and processing for data-driven analytics.

San Diego, Ca, Us

• Identifies, evaluates and implements new technologies and methods to improve quality and efficiency of HTS campaigns and SAR profiling.• Develops and executes non-routine and exploratory in vitro assays to support characterization of small molecules and targeted protein degraders such as mechanistic studies and kinetic HiBiT degradation assays. • Mentors and provides guidance for the skill and career development of direct reports and trainees.• Executed focused library monotherapy and combinatorial screens as well as supporting SAR and orthogonal assays.

New York, New York, Us

•Develops, optimizes and miniaturizes biochemical and cellular assays amenable to automated high-throughput screening in 384-well formats. Acts as a resource individual to ~15 colleagues and assists in automating and miniaturizing their existing assays for improved throughput, efficiency and cost.•Conducts mid-to-high throughput screening (Kinase Glo, ADP Glo, FP, SPA, TR-FRET, efflux and reporter assays) of chemical libraries, specialty compound collections and subset files aimed at identifying small molecule cancer therapeutics primarily in epigenetic, metabolic and immuno-oncology platforms.•Executes and analyzes kinetic and mechanistic studies to characterize enzyme targets, as well as selectivity screening of potential lead compounds.•Develops and implements orthogonal assays for further characterization of confirmed hits. •Performs potency and Ki assays to drive in vitro SAR, as well as assays for SIR (counter-screens, redox, label free aggregation), that help identify, triage and de-risk pan-assay interference compounds (PAINS).•Facilitates method transfer, oversees and serves as point person for uHTS screens conducted by contracted third parties.•Authors electronic protocol registration manuscripts as requisite step in capturing discovery data into the global database and facilitate data access/dissemination across global Pfizer sites.•Participates in evaluation of current and emerging technologies in drug discovery in order to incorporate and improve existing workflow (e.g., spearheaded the implementation of acoustic dispense technology in various aspects of our cellular and biochemical assay workflows).•Identifies as an Activity-base power user for the BPS group and assists colleagues in their database user needs. •Regularly presents assay development updates, screening and characterization data to project teams.

New York, New York, Us

Switzerland 🇨🇭 , Ch

• Developed, adapted and implemented automated high-throughput biochemical screens aimed at identifying small molecule therapeutics for both oncology and autoimmune indications• Determined potency, binding, kinetic mode of inhibition, solubility and selectivity of compounds in hit characterization, validation and subsequent stages of drug discovery process• Performed high volume data analyses and subsequent reporting and publication using Genedata and Activity Base • Conducted routine biochemical potency assays to support and drive project SAR studies • Developed a TR-FRET assay and successfully implemented and screened Roche full library (~1.2M compounds) followed by hit confirmation and validation by IC50 determination and label-free binding studies • Developed an AlphaLISA assay for identifying small molecule p53 tumor suppressor stabilizers/activators• Identified novel tyrosine kinase inhibitors through thermal shift (differential scanning fluorimetry) screening of Roche fragment library • Experienced with automation and semi-automated workstation and robotic systems such as liquid handling and signal detection systems • Presented data to upper management as well as to peers during regular meetings

Morris Plains, New Jersey, Us

• Provided technical support for the Preclinical department in the in vitro functional characterization and elucidation of the mechanisms of action of humanized monoclonal antibodies and antibody conjugates, which included conduct of ELISA and cell-based assays (in colorimetric, fluorescent and chemiluminescent detection platforms) that measure proliferation (MTS, BrdU incorporation), cytotoxicity (CDC, ADCC, LDH release), viability, potency and apoptosis (guava nexin) assays, as well as antigen binding and affinity• Proficiently maintained cell cultures of various solid tumor lines (breast, pancreatic, prostate, lung, epidermal, colon, gastric, ovarian, thyroid, cervical) and B cell malignancies, as well as large-scale hybridoma cultures for antibody generation• Performed routine mycoplasma testing using commercially available kits • Actively participated in assay development, method qualification, validation and method transfer in support of Investigational New Drug (IND) submissions• Maintained proper laboratory data documentation and subsequently evaluated and performed statistical analyses using Excel and GraphPad Prism• Presented data to upper management as well as to peers during regular meetings• Prepared technical reports and summaries for Preclinical documents• Supervised and trained personnel

New York, Ny, Us

• Carried out quantitative analysis of biological molecules in clinical and non-clinical serum samples generated from animal and human studies by radioimmunoassay (RIA) using in-house or commercially available 3H and 125I RIA kits• Performed Chloramine-T radioiodinations• Accomplished in vitro ADME studies evaluating the role of liver microsomal and cytosolic cytochrome P450 enzymes in the metabolic fate of synthetic progestins• Prepared buffers, serum controls, and standard solutions• Performed minor animal surgical procedures (subdermal implantation, castration, isolation of rat pituitary gland, and blood collection)• Performed basic molecular techniques such as RNA isolation, RT-PCR and gel electrophoresis • Implemented ‘Good Laboratory Practices’ (GLP) guidelines including proper data documentation, method validation and maintenance, standardization, normalization and calibration of delicate equipment• Performed t- tests and ANOVA statistical data analyses• Supervised and trained new personnel• Wrote and executed a variety of Standard Operating Procedures (SOPs)• Facilitated procurement of chemicals and laboratory supplies

Ms, Biology

Bs, Biology

Education record

Molecular Bioscience